EFFICACY OF TRANSARTERIAL TARGETED TREATMENTS ON SURVIVAL OF PATIENTS WITH HEPATOCELLULAR-CARCINOMA - AN ITALIAN EXPERIENCE

被引:1
作者
STEFANINI, GF
AMORATI, P
BISELLI, M
MUCCI, F
CELI, A
ARIENTI, V
ROVERSI, R
ROSSI, C
RE, G
GASBARRINI, G
机构
[1] UNIV BOLOGNA, IST PATOL MED 1, BOLOGNA, ITALY
[2] UNIV BOLOGNA, SERV CARDIODIAGNOST, BOLOGNA, ITALY
[3] UNIV BOLOGNA, REPARTO MED URGENZA, BOLOGNA, ITALY
[4] OSPED BELLARIA, SERV RADIOL DIAGNOST, BOLOGNA, ITALY
[5] UNIV CATTOLICA SACRO CUORE, IST CLIN MED, ROME, ITALY
关键词
MEDICAL ONCOLOGY; LIVER; HEPATOCELLULAR CARCINOMA; ANGIOGRAPHY; THERAPY; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; CIRRHOSIS;
D O I
10.1002/1097-0142(19950515)75:10<2427::AID-CNCR2820751007>3.0.CO;2-J
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background. Most patients with hepatocellular carcinoma (HCC) are not suitable for surgical therapy. Systemic chemotherapy, immunotherapy, and hormonotherapy have not had convincingly acceptable results. Therefore, transarterial catheter-targeted therapies such as intraarterial chemotherapy (IAC), possibly followed by transcatheter arterial chemoembolization (TACE), have been proposed. Methods. A survival analysis curve was drawn using the Kaplan-Meier method for 164 patients, 100 with HCC who underwent TACE (69) or IAC (31), and a matched historic group of 64 who did not receive specific antineoplastic treatment. Results. A significantly more favorable survival was observed for TACE-treated patients compared with IAC-treated patients (P < 0.001); TACE- and IAC-treated patients had a statistically superior survival than that of untreated patients (P < 0.001 and P < 0.025, respectively). This difference was still significant (P < 0.001) when the patients were subdivided into Classes A and B and Stages I and II following Child's and Okuda's criteria. The TACE- and IAC-treated groups had a good relationship between technical efficacy of therapy and survival. Stratifying the patients according to the degree of iodized oil (Lipiodol Ultrafluid, Guerbet, Aulnay-Sous-Bois, France) uptake in the three groups with Group 1 having an uptake greater than 75% of tumor mass, Group 2 having an uptake of 50%-75%, and Group 3 having an uptake less than 50%, survival at 6, 12, 24, 36, and 48 months was calculated as 94%, 88%, 67%, 53%, and 30%, respectively, for Group 1; 86%, 68%, 13%, 13%, and 0% for Group 2, and 43%, 23%, 6%, 6%, and 0% for Group 3 (Group 1 vs. Group 2: P < 0.001; Group 1 vs. Group 3: P < 0.001; Group 2 vs. Group 3: P < 0.001, respectively). The most important side effects after the intraarterial procedure were fever (46.2%), abdominal pain (36.6%), chemical cholecystitis (8%), and pancreatitis (1.7%). Death strictly related to treatment occurred in two patients; one had massive bleeding due to ruptured esophageal varices, and the other had a subphrenic abscess of a superficial HCC of the VIII segment. Conclusions. Transcatheter arterial chemoembolization and IAC were effective and relatively safe, and the authors believe that they have a primary role in treating patients with unresectable HCC larger than 5 cm; iodized oil uptake can be considered a suitable prognostic marker.
引用
收藏
页码:2427 / 2434
页数:8
相关论文
共 46 条
[1]   PROGNOSIS OF UNRESECTABLE HEPATOCELLULAR-CARCINOMA - AN EVALUATION BASED ON MULTIVARIATE-ANALYSIS OF 90 CASES [J].
AKASHI, Y ;
KOREEDA, C ;
ENOMOTO, S ;
UCHIYAMA, S ;
MIZUNO, T ;
SHIOZAKI, Y ;
SAMESHIMA, Y ;
INOUE, K .
HEPATOLOGY, 1991, 14 (02) :262-268
[2]  
[Anonymous], 1990, Cancer, V66, P135
[3]  
ARIENTI V, 1991, J HEPATOL S, V13
[4]   PRIMARY-TREATMENT OF HEPATOCELLULAR-CARCINOMA BY ARTERIAL CHEMOEMBOLIZATION [J].
BISMUTH, H ;
MORINO, M ;
SHERLOCK, D ;
CASTAING, D ;
MIGLIETTA, C ;
CAUQUIL, P ;
ROCHE, A .
AMERICAN JOURNAL OF SURGERY, 1992, 163 (04) :387-394
[5]   LIVER RESECTIONS IN CIRRHOTIC-PATIENTS - A WESTERN EXPERIENCE [J].
BISMUTH, H ;
HOUSSIN, D ;
ORNOWSKI, J ;
MERIGGI, F .
WORLD JOURNAL OF SURGERY, 1986, 10 (02) :311-317
[6]   HEPATIC INTRAARTERIAL LIPIODOL - TECHNIQUE, SEMIOLOGIC PATTERNS, AND VALUE FOR HEPATIC-TUMORS [J].
BRUNETON, JN ;
KERBOUL, P ;
GRIMALDI, C ;
NORMAND, F ;
BALUMAESTRO, C ;
RAMPAL, P ;
DELMONT, J .
GASTROINTESTINAL RADIOLOGY, 1988, 13 (01) :45-51
[7]  
BRUNETON JN, 1985, RADIOLOGY, V157, P313
[8]   CONTROLLED TRIAL OF TAMOXIFEN IN PATIENTS WITH ADVANCED HEPATOCELLULAR-CARCINOMA [J].
CEREZO, FJM ;
TOMAS, A ;
DONOSO, L ;
ENRIQUEZ, J ;
GUARNER, C ;
BALANZO, J ;
NOGUERAS, AM ;
VILARDELL, F .
JOURNAL OF HEPATOLOGY, 1994, 20 (06) :702-706
[9]  
ELBA S, 1994, ITAL J GASTROENTEROL, V26, P66
[10]   PROSPECTIVE CONTROLLED TRIAL WITH ANTIESTROGEN DRUG TAMOXIFEN IN PATIENTS WITH UNRESECTABLE HEPATOCELLULAR-CARCINOMA [J].
FARINATI, F ;
DEMARIA, N ;
FORNASIERO, A ;
SALVAGNINI, M ;
FAGIUOLI, S ;
CHIARAMONTE, M ;
NACCARATO, R .
DIGESTIVE DISEASES AND SCIENCES, 1992, 37 (05) :659-662